Novel DNA-directed alkylating agents consisting of naphthalimide, nitrogen mustard and lexitropsin moieties: Synthesis, DNA sequence specificity and biological evaluation

Anti-Cancer Drug Design

Volumn 11, Issue 8, 1996, Pages 581-596

  Gupta, Rajan ^a   Liu, Jixiang ^a   Xie, Guojian ^a   Lown, J William ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

DNA directed alkylating agents; Naphthalimides; Sequence specificity; Synthesis

Indexed keywords

ADENINE; ALKYLATING AGENT; CHLORMETHINE; DISTAMYCIN A; GUANINE; LEXITROPSIN; NAPHTHALENE DERIVATIVE; NAPHTHALIMIDE; UNCLASSIFIED DRUG;

ALKYLATION; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DNA ALKYLATION; DNA BINDING; DNA SEQUENCE; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NASOPHARYNX CANCER; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

1-NAPHTHYLAMINE; ANTINEOPLASTIC AGENTS, ALKYLATING; BASE SEQUENCE; BINDING SITES; DNA; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMIDES; MECHLORETHAMINE; MOLECULAR SEQUENCE DATA; NETROPSIN; TUMOR CELLS, CULTURED;

BRASSICACEAE;

EID: 0030474335     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. ARCAMONE, F.M.. ANIMATI, F A., BARBIERI, B, CONFIGLIACCHI, E., D'ALESIO, R, GERONI, C, GIULIANI, E.C., LAZZARI, E, MENOZZI, M ,MONGELLI, N., PENCO, S & VERINI, M.A. (1989). Synthesis, DNA binding properties and antitumor activity of novel distamycin derivatives. Journal of Medicinal Chemistry, 32, 774.
2. BOGER, D. L., ZARRINMAYEH, H., MUNK, S. A. KITOS, P A & SUNTORNWAT, O (1991). Demonstration of a pronounced effect of noncovalent binding selectivity on the (+)-CC-1065 DNA alkylation and identification of the pharmacophore of the alkylation subunit. Proceedings of the National Academy of Sciences, USA, 88, 1431.
3. BOUSQUET, P. F , BRANA. M F, CONLON, D., FITZGERALD, K M., PERRON, D , COCCHIARO, C., MILLER, R , MORAN, M . GEORGE, J., QIAN, X.D, KEILHAUER, G & ROMERDAHL, C A. (1995). Preclinical evaluation of LU 79553: a novel bis-naphthalimide with potent antitumor activity. Cancer Research, 55, 1176.
4. BRANA, M.F, SANZ, A M., CASTELLANO, J.M. ROLDAN, C.M. & ROLDAN, C (1981). Synthesis and cytostatic activity of benz(d,e)isoquinolin-1,3-diones. Structure-activity relationships. European Journal of Medicinal Chemistry - Chemical Therapeutics, 16, 61.
5. BRANA, M.F., CASTELLANO, J M , MORAN, M , VEGA, M.J.P, ROMERDAHL, C.R , QIAN, X D., BOUSQUET, P, EMLING, F, SCHLICK, E. & KEILHAUER, G. (1993). Bis-naphthalimides: a new class of antitumor agents. Anti-Cancer Drug Design, 8, 257.
6. BUBLEY, G.I., OGATA, G.K., DUPUIS, N.P. & TEICHER, B.A (1994). Detection of sequence specific antitumor alkylating agent DNA damage from cells treated in culture and from a patient. Cancer Res., 54, 6325.
7. EMLING, F, KLUGE, M., KEILHAUER, G, DORPER, T, DAUM, L , MOLLER, A , HILLEN, H , SCHOLLMEIER, K , BRANA, M.F & SCHLICK, E. (1990). Evaluacion preclinica de nuevos compuestos antitumourales. Reviews on Cancer, 4, 3.
8. FONTANA, M., LESTINGI, M., MONDELLO, C. BRAGHETTI, A., MONTECUCCO, A & CIARROCHI, G (1992). DNA binding properties of FCE 24517, an electrophilic distamycin analogue. Anti-Cancer Drug Design, 7, 131.
9. GILLIES, R.J. DIDIAC, N. & DENTON, M (1986). Determination of cell number in monolayer cultures. Analytical Biochemistry, 159, 109.
10. GUO, D., GUPTA, R. & LOWN, J.W. (1993). DNA sequence selective binding of head-to-tail linked bis-lexitropsins: relation of phasing to cytotoxic potency. Anti-Cancer Drug Design, 8, 369.
11. GUPTA, R., WANG, H, HUANG, L. & LOWN, J.W (1994a). Design, synthesis, DNA sequence preferential alkylation and biological evaluation of nitrogen mustard derivatives of Hoechst 33258 analogues. Anti-Cancer Drug Design, 10, 25.
12. GUPTA, R., XIE, G. & LOWN, J W. (1994b). Hybrid molecules containing propargylic sulfones and DNA minor groove-binding lexitropsins: synthesis, sequence specificity of reaction with DNA and biological evaluation. Gene, 149, 81.
13. HARTLEY, JA, GIBSON, N W., KOHN, K.W. & MATTES, W.B. (1986). DNA sequence selectivity of guanine-N7 alkylation by three antitumor chloroethylating agents. Cancer Research, 46, 1943.
14. HURLEY, L H , WARPEHOSKI, M A , LEE, C.H., MCGOVREN, J P, SCAHILL, T.A., KELLY, R.C., MITCHELL, M.A , WICNIENSKI, N A., GEBHARD, I., JOHNSON, P.D. & BRADFORD, V.S. (1990). Sequence specificity of DNA alkylation by the unnatural enantiomer of CC-1065 and its synthetic analogs. Journal of the American Chemistry Society, 112, 4633.
15. ISABELLA, P.D., ZUNINO, F. & CAPRANINO, G. (1995). Base sequence determinants of amonafide stimulation of topoisomerase II DNA cleavage. Nucleic Acids Research, 23, 223.
16. KIRSHENBAUM, M R., CHEN, S.F., BEHRENS, C.H., PAPP, L M., STAFORD, M.M , SUN, JH , BEHRENS, D.J.-L., FREDERICKS, JR., POLKUS, S T, SIPPLE, P., PATTEN, A.D., DEXTER, D., SEITZ, S.P. & GROSS, J L. (1994). (R,R)-2,2′-[1,2-Ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]-bis[5- nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro. Cancer Research, 54, 2199.
17. LOWN, J W (1992). Lexitropsins in antiviral drug development. Antiviral Research, 17, 179.
18. LOWN. J W (1994). DNA recognition by lexitropsins, minor groove binding agents. Journal of Molecular Recognition, 7, 79.
19. MCRIPLEY, R J, HORWITZ, PE B., CZERNIAK, P.M., DIAMOND, R I., DIAMOND, M.A., MILLER, J L.D , PAGE, R.J., DEXTER, D.L., CHEN, S.F, SUN, J H., BEHRENS, C H, SEITZ. S.P & GROSS, J L. (1994). Efficacy of DMo 840: a novel bisnaphthalimide cytotoxic agent with human solid tumour xenograft selectivity. Cancer Research, 54, 159.
20. MALVIYA, V.K., LIU, P.Y., ALBERTS, D.S., SURWIT, E.A , CRAIG, J B. & HANNINGAN, E.V. (1992). Evaluation of amonafide in cervical cancer, phase II. American Journal of Clinical Oncology, 15, 41.
21. MATTES, W.B., HARTLEY, J.A. & KOHN, K.W. (1986). Mechanism of DNA strand breakage by piperidine at sites of N7-alkylguanines. Biochimica et Biophysica Acta, 868, 71.
22. MAXAM, A M & GILBERT, W. (1980). Sequencing end-labelled DNA with base specific chemical cleavages. Methods in Enzymology, 65, 499.
23. PRATT, W.B. & RUDDON, A W (1979). The Anticancer Drugs. Oxford University Press: Oxford.
24. RAO, K E & LOWN, J.W. (1990). Mode of action of saframycin antitumour antibiotics: sequence selectivities in the covalent binding of saframycins A and S to DNA. Chemical Research in Toxicology, 3, 262.
25. RAO, K.E & LOWN, J.W. (1992). DNA sequence selectivities in the covalent bonding of antibiotic saframycins MX1, MX3, A and S deduced from MPE.Fe(II) footprinting and exonuclease III stop assays. Biochemistry, 31, 12076.
26. RAO, K E , SHEA, R G, YADAGIRI, B. & LOWN, J.W. (1990). Molecular recognition between oligopeptides and nucleic acids: DNA sequence specificity and binding properties of thiazole lexitropsins incorporating the concepts of base site acceptance and avoidance. Anti-Cancer Drug Design, 5, 3.
27. ROSELL, R , CARLES, J , ABAD, A , RI BELLES, N , BARNADAS, A. BENAVIDES, A. & MARTIN, M (1992). Phase I Study of mitonafide in 120 h continous infusion in non small lung cancer. Investigational New Drugs, 10, 71.
28. SAITO, I. (1992). Photochemistry of highly organized biomolecules: sequence selective photoreaction of DNA. Pure & Applied Chemistry, 64, 1305.
29. SZYBALSKI, W & IYER, V.N. (1967). The mitomycins and porfiromycins. In Antibiotics I. Mechanism of Action. Gottlieb, D. & Shaw, P.D. (eds), p. 211. Springer Verlag: New York.
30. XIE, G & LOWK, J W (1994). A facile synthesis of staurosperin aglycone. Tetrahedron Letters, 35, 5555.
31. XIE, G., GUPTA, R. & LOWN, J.W (1995). Design, synthesis, DNA sequence preferential alkylation and biological evaluation of nitrogen mustard derivatives of distamycin and netropsin analogues. Anti-Cancer Drug Design, 10, 389.